Biparametric prostate MRI: impact of a deep learning-based software and of quantitative ADC values on the inter-reader agreement of experienced and inexperienced readers

[1] Mottet N(2021)EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 79 243-262

[2] van den Bergh RCN(2018)Screening for prostate cancer: US preventive services task force recommendation statement JAMA. 319 1901-214

[3] Briers E(2018)Clinical utility of multiparametric magnetic resonance imaging as the first-line tool for men with high clinical suspicion of prostate cancer Eur Urol Oncol 1 208-351

[4] Grossman DC(2019)Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2 Eur Urol 76 340-109

[5] Curry SJ(2019)Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study Lancet Oncol 20 100-1777

[6] Panebianco V(2018)MRI-targeted or standard biopsy for prostate-cancer diagnosis N Engl J Med 378 1767-388

[7] Valerio MC(2015)Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies: Biparametric MRI for prostate cancer detection BJU Int 115 381-822

[8] Giuliani A(2017)Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study The Lancet 389 815-578

[9] Turkbey B(2019)Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study Eur Urol 75 570-W241

[10] Rosenkrantz AB(2018)Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis Am J Roentgenol 211 W226-611

[1] Mottet N(2021)EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 79 243-262

[2] van den Bergh RCN(2018)Screening for prostate cancer: US preventive services task force recommendation statement JAMA. 319 1901-214

[3] Briers E(2018)Clinical utility of multiparametric magnetic resonance imaging as the first-line tool for men with high clinical suspicion of prostate cancer Eur Urol Oncol 1 208-351

[4] Grossman DC(2019)Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2 Eur Urol 76 340-109

[5] Curry SJ(2019)Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study Lancet Oncol 20 100-1777

[6] Panebianco V(2018)MRI-targeted or standard biopsy for prostate-cancer diagnosis N Engl J Med 378 1767-388

[7] Valerio MC(2015)Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies: Biparametric MRI for prostate cancer detection BJU Int 115 381-822

[8] Giuliani A(2017)Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study The Lancet 389 815-578

[9] Turkbey B(2019)Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study Eur Urol 75 570-W241

[10] Rosenkrantz AB(2018)Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis Am J Roentgenol 211 W226-611